<DOC>
	<DOCNO>NCT02135666</DOCNO>
	<brief_summary>The purpose study ass long-term persistence immunity hepatitis A B adult vaccinate 16-20 year earlier combine hepatitis A hepatitis B vaccine , Twinrix .</brief_summary>
	<brief_title>Evaluation Long-term Hepatitis A B Antibody Persistence Healthy Adult Subjects , Primed 16 20 Years Earlier With GSK Biologicals ' Combined Hepatitis A B Vaccine , TwinrixÂ® ( SB208127 ) Study HAB-084 ( 208127/084 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female receive two/three dos Twinrix accord his/her group allocation study HAB084 ( 208127/084 ) , receive dose hepatitis A and/or B vaccine since . Written inform consent obtain subject . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug within six month prior study entry . Inhaled topical steroid allow . Administration longacting immunemodifying drug within six month prior study entry . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Administration hepatitis A and/or B vaccine time since completion primary vaccination series HAB084 ( 208127/084 ) study , include challenge dose study vaccine , part study procedure , longterm persistence phase . Documented history hepatitis A B disease since completion primary vaccination series HAB084 ( 208127/084 ) study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Administration immunoglobulin within six month prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Twinrix</keyword>
	<keyword>Long-term follow-up</keyword>
	<keyword>Persistence</keyword>
	<keyword>Hepatitis A</keyword>
	<keyword>Antibody</keyword>
	<keyword>Immunity</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Combination vaccine</keyword>
	<keyword>Adult</keyword>
</DOC>